The end point is just the beginning

Journal of Diabetes Science and Technology

Volumn 5, Issue 5, 2011, Pages 1287-1289

  Muchmore, Douglas ^a  

^a Halozyme Therapeutics Inc   (United States)

Author keywords

Clinical trials; Diabetes treatment; Glycosylated hemoglobin; Hypoglycemia

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; HUMAN; METABOLISM; OUTCOME ASSESSMENT; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 84857403648     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500538     Document Type: Note

References (11)

1. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf. Accessed September 17, 2010.
2. The Diabetes Control and Complications Trial Research Group. The efect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329(14):977-86.
3. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29(8):1607-19.
4. Montori VM, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D, Alonso J, Akl EA, Domingo-Salvany A, Mills E, Wu P, Schünemann HJ, Jaeschke R, Guyatt GH. Validity of composite end points in clinical trials. BMJ. 2005;330(7491):594-6.
5. Ferreira-González I, Busse JW, Heels-Ansdell D, Montori VM, Akl EA, Bryant DM, Alonso-Coello P, Alonso J, Worster A, Upadhye S, Jaeschke R, Schünemann HJ, Permanyer-Miralda G, Pacheco-Huergo V, Domingo-Salvany A, Wu P, Mills EJ, Guyatt GH. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334(7597):786.
6. Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA. 2010;303(3):267-8.
7. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ. 2010;341:c3920.
8. Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007;30(11):2794-9.
9. Seck TL, Engel SS, Williams-Herman DE, Sisk CM, Golm GT, Wang H, Kaufman KD, Goldstein BJ. Sitagliptin more efectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide. Diabetes Res Clin Prac. 2011.Epub ahead of print.
10. Charbonnel B, Thiriet C, Guerci B. Reaching a clinically relevant compostite end point of HbA1c target < 7% - no hypoglycaemia - no weight gain, with liraglutide vs other T2D therapies. Presented at: American Diabetes Association Annual Meeting, Orlando, FL, June 25-29, 2010. Abstract 593-P.
11. Fleming A. Counterpoint - the end point: less is more. J Diabetes Science Technol. 2011;5(5):1290-3.